ASH 2021 | Updates in the DLBCL treatment landscape
John Burke, MD, Rocky Mountain Cancer Centers, US Oncology Research, Aurora, CO, discusses developments in the field of diffuse large B-cell lymphoma (DLBCL) treatment. Whilst R-CHOP and autologous stem cell transplants are the standard first-line and second-line treatments for DLBCL respectively, novel therapies have demonstrated superior efficacy. Polatuzumab vedotin, an antibody-drug conjugate, and R-CHP have shown to be a promising first-line treatment regimen in the Phase III POLARIX trial (NCT03274492), and ongoing trials have demonstrated the potential of chimeric antigen receptor (CAR) T-cell therapies to replace autologous stem cell transplantation. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
